A short clip from the interview on Weight Loss Pharmaceuticals
In this short clip from the interview on Weight Loss Pharmaceuticals, Samantha LaDuc and Dr. Alex Kenton discuss the pharmaceutical company Viking Therapeutics and its drug development, specifically focusing on a drug for non-alcoholic steatohepatitis (NASH) that has completed phase two trials.
They consider the potential of Viking being acquired by larger pharmaceutical companies like Merck, given its promising drug and recent stock market performance. They delve into the complexities of getting a drug fully approved and the strategic benefits of acquisition for both the smaller biotech and the larger pharma entities.
Additionally, they touch on the scientific aspects of drug trials, emphasizing the importance of statistical significance in evaluating drug efficacy.
00:00 Introduction
00:54 Market Response to Viking’s Developments
01:22 Potential Acquisition of Viking by Larger Companies
01:58 Discussion on Merck’s Potential and Personal Anecdote
02:46 Rumors of Viking Acquisition and Investment Challenges
03:09 FDA Approval Process and Acquisition Benefits
04:45 Merck as a Potential Acquirer of Viking
05:40 Significance of the Drug’s Side Effect Profile
